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ABSTRACT
Motivation: Deregulated signaling cascades are known to play a
crucial role in many pathogenic processes, among them are tumor
initiation and progression. In the recent past, modern experimental
techniques that allow for measuring the amount of mRNA transcripts
of almost all known human genes in a tissue or even in a single cell
have opened new avenues for studying the activity of the signaling
cascades and for understanding the information ﬂow in the networks.
Results: We present a novel dynamic programming algorithm for
detecting deregulated signaling cascades. The so-called FiDePa
(Finding Deregulated Paths) algorithm interprets differences in the
expression proﬁles of tumor and normal tissues. It relies on the well-
known gene set enrichment analysis (GSEA) and efﬁciently detects all
paths in a given regulatory or signaling network that are signiﬁcantly
enriched with differentially expressed genes or proteins. Since our
algorithm allows for comparing a single tumor expression proﬁle with
the control group, it facilitates the detection of speciﬁc regulatory
features of a tumor that may help to optimize tumor therapy. To
demonstrate the capabilities of our algorithm, we analyzed a glioma
expression dataset with respect to a directed graph that combined
the regulatory networks of the KEGG and TRANSPATH database. The
resulting glioma consensus network that encompasses all detected
deregulated paths contained many genes and pathways that are
known to be key players in glioma or cancer-related pathogenic
processes. Moreover, we were able to correlate clinically relevant
features like necrosis or metastasis with the detected paths.
Availability: C++ source code is freely available, BiNA can be
downloaded from http://www.bnplusplus.org/.
Contact: ack@bioinf.uni-sb.de
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
Modern high-throughput techniques for quantifying gene and
protein expression combined with state-of-the-art bioinformatics
approaches have opened new avenues for studying physiological
and pathological processes on the molecular level. Pathway analysis
∗To whom correspondence should be addressed.
has been broadly applied within biomedical sciences, especially
in cancer research, where it is mainly used to elucidate the
mechanisms of tumor progression (Ganter and Giroux, 2008).
Differential network analysis has emerged as a research area that
aims at developing novel approaches for detecting and quantifying
differences in the activities of signaling cascades and metabolic and
regulatory networks between cancer and normal cells.
In the early stages of differential expression analysis, techniques
for identifying genes with varying expression patterns in cancer and
normal cells have been developed. More recently, the focus has
shifted toward gene set analysis approaches that aim at revealing
the enrichment of genes or proteins in biological categories and
networks. Gene set analysis tools such as FatiGO (Al-Shahrour
et al., 2004), ErmineJ (Lee et al., 2005), WebGestalt (Zhang et al.,
2005), Babelomics (Al-Shahrour et al., 2005) or GeneTrail (Backes
et al., 2007) enable the user to detect biochemical pathways [as
KEGG (Kanehisa, 2002; Kanehisa et al., 2006) or TRANSPATH
(Krull et al., 2006)], Gene Ontology categories (Ashburner et al.,
2000) or other functional biological groups that are signiﬁcantly
enriched or depleted for deregulated genes. Here, one of the most
commonly applied approaches is the so-called gene set enrichment
analysis (GSEA; Mootha et al., 2003; Subramanian et al., 2005).
An overview of different approaches and methods can be found in
Nam and Kim (2008).
Since most gene set analyses methods are designed to examine
arbitrary biological categories, the topology of biological networks,
if available, is usually not taken into consideration by these tools.
In recent years, however, several approaches have been suggested
that exploit the network topology. One of the ﬁrst methods tailored
for the interpretation of gene expression data in the light of the
network topology applies clustering techniques to detect pathways
withco-expressedgenes(FellenbergandMewes,1999).Morerecent
algorithms score given network topologies based on experimental
data of the network’s participants (Ideker et al., 2002; Kurhekar
et al., 2002; Rahnenfuehrer et al., 2004). Other promising methods
that search for differentially regulated pathways rely on Petri Nets
(Cabusora et al., 2005; Kueffner et al., 2000; Zien et al., 2000).
Xiong et al. (2004) presented an algorithm for network-based
regulatory pathway analysis, which is based on extreme pathway
analysis,amethodthatismostlyusedfortheevaluationofmetabolic
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networks.Topology-basedclassiﬁcationtechnologieshavealsobeen
successfully applied to distinguish cancer subclasses (Liu et al.,
2006). Likewise, Chuang et al. (2007) presented an network-based
approach leading to an improved accuracy in the classiﬁcation of
metastatic versus non-metastatic breast cancers, which relies on the
mutual information (Shannon, 1984) as a scoring function. Most
recently, Liu et al. (2007) published a sophisticated method, called
‘Gene Network Enrichment Analysis’, which is similar to standard
‘GSEA’and applies hypothesis testing to evaluate pathways. Given
the continuously increasing number of network-based analyses,
web-based tools such as GenMAPP (Dahlquist et al., 2002) start to
offer corresponding functionality (Salomonis et al., 2007). Besides
heuristic approaches, methods that identify optimal sub-structures
with respect to a given scoring function are also available. Dittrich
et al. (2008) used Integer Linear Programming to detect deregulated
modules in protein–protein interaction networks. Ulitsky et al.
(2008) presented an algorithm for identifying minimal connected
subnetworks in which the number of dysregulated genes in each
diseased sample exceeds a given threshold. The aforementioned
studies are only a selection from the broad body of approaches
that show the extremely fast development of this growing ﬁeld of
research.
In this study, we present a novel algorithm for detecting
differentially regulated paths in a given biological network with
known topology based on GSEA. Besides the network, its
participants and topology, the input of the algorithm consists of a
list S of n genes that are sorted with respect to their expression
differences between two investigated states, e.g. cancer and normal
tissue. The algorithm interprets each path p of a certain length
l in the given network as a biological category Cp that consists
of the l genes represented by the nodes of the path p. Using a
Kolmogorov–Smirnov-like test that computes whether the set of
genes Cp belonging to the path p are equally distributed in the
expression list or accumulate on the top or bottom of the list, we
determine if the given path p is deregulated (contains a large number
of up- or downregulated genes) or not. The applied Kolmogorov–
Smirnov-like test is a standard test of GSEA(Lamb et al., 2003) that
computes the running sum of all genes in S. Hereby, the sorted list
S is processed from top to bottom. Whenever a gene belonging to
Cp is detected, the running sum is increased by n−l, otherwise it is
decreased by l. The value of interest is the running sum’s maximal
deviation from zero, for which a P-value can be computed (Keller
et al., 2007). Since the number of paths is growing exponentially
with the length l, the brute-force approach that enumerates all paths
of length l and computes the running sum for each path separately
is applicable only for very small values of l.
To identify the most signiﬁcant paths efﬁciently, we developed
a novel dynamic programming algorithm, called FiDePa (Finding
Deregulated Paths). Our algorithm computes the paths of length
l with the smallest P-value, i.e. the paths having the maximal
deviation of its running sum from zero. In order to facilitate
the interpretation of the ﬁndings, the resulting paths have to be
visualized in a well-arranged manner. To this end, we added
respective functionality to our graph drawing tool ‘BiNA’(Kuentzer
et al., 2006; Sirava et al., 2002) that enables the user to visualize
and compare signiﬁcant paths.
As a ﬁrst application of FiDePa, we studied pathogenic processes
in human neoplasms by evaluating expression proﬁles of 100
glioma patients [WHO grades III and IV, extracted from the Gene
Expression Omnibus (GEO; Barrett and Edgar, 2006; Edgar et al.,
2002) dataset GDS1815 (Phillips et al., 2006)]. We selected this
glioma expression proﬁle dataset since a variety of clinical and
histological data (WHO grade, microvascular proliferation status,
necrosis and survival time) were available for the samples. As
a control group, we selected 158 expression proﬁles [GDS596
(Su et al., 2004)] of physiologically unaffected tissues. To detect
differences and similarities between the tumors, we ﬁrst computed
the signiﬁcant paths for each patient separately. Based on these
results, we constructed a glioma consensus network by unifying
all paths detected with the 100 expression proﬁles. To facilitate
the comparison of patients, the signiﬁcant paths of a single tumor
(patients) or groups of tumors can be projected onto the consensus
network. While the consensus network identiﬁed most pathways,
known to be related to glioma, the comparisons of different tumors
revealed substantial differences in the activities of crucial signaling
cascades.
2 ALGORITHM
In this section, we lay the theoretical basics for our new dynamic
programming algorithm.We ﬁrst provide some basic deﬁnitions and
notations and then describe in detail, how the running sum statistics
and the corresponding P-values are computed for an arbitrary
biological category.
2.1 Deﬁnitions and notations
Biological networks are often represented as directed graphs
G={V,E}, where the vertices (nodes) V ={v1,...,vq} represent
genes, proteins or other compounds and the directed edges
e(vi,vj)∈E (arcs) represent interactions or reactions between the
respective compounds. A path of length l in G is a sequence
vp1,...,vpi,vpi+1,...,vpl of l nodes, where each pair vpi,vpi+1 of
consecutivenodesisconnectedbyadirectededge(arc),whichstarts
in vpi and ends in vpi+1. We denote the set of all paths of length l by
Pl and the subset of paths in Pl that end in the node vk by Pl(vk).
The set N(vk) of predecessors of node vk is deﬁned as
N(vk)={vs∈G|∃e(vs,vk)∈E}. (1)
Besides the graph G, the input of the algorithm consists of a gene
list S of length n. The genes in the list S are sorted with respect
to an arbitrary criterion, e.g. their fold changes of expression values
between two investigated states. Given a gene represented by a node
v in the graph G, we denote the rank of the gene in the sorted list S
as r(v).
2.2 Computing signiﬁcance values
Our algorithm detects the statistically most signiﬁcant paths in G of
length up to a user-deﬁned bound m.To compute signiﬁcance values
of a path p of length l, we apply a method that is known from gene
set analysis, the so-called GSEA.
Performing GSEA for a biological category Cp representing a
path p of length l and a sorted list S of n genes of which l belong to
Cp means that a running sum statistic RS is computed for S. Here,
we assume for simplicity that all genes in the respective biological
category are contained in S. RS statistics evaluate whether the genes
of Cp are accumulated on top or bottom of the sorted list or whether
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they are randomly distributed. Hereby, the sorted list is processed
from top to bottom:
RS∗
p :=0
RSp[0]:=0
for (i=1...n)
if (S[i]∈Cp) RSp[i]:=RSp[i−1]+n−l
else RSp[i]:=RSp[i−1]−l
if (|RSp[i]|>|RS∗
p|) RS∗
p :=RSp[i]
In the case of standard unweighted GSEA, whenever a gene
belonging to Cp is detected, the running sum is increased by
n−l, otherwise it is decreased by l. The value of interest is the
running sum’s maximal deviation from zero, denoted as RS∗
p. The
signiﬁcance value of the score RS∗
p can be calculated by a dynamic
programming algorithm that computes the exact number of possible
running sum statistics with higher deviation than RS∗
p. For details
on the implemented algorithm we refer to Keller et al. (2007).
To simplify matters, we will ignore the fact that we have to
consider the absolute values of the running sums and we will present
a procedure that calculates the largest non-negative value of the
running sum. The smallest running sum value can be computed by
applying the same algorithm to the inverted gene list that starts with
the last element in S.
Our dynamic programming algorithm is based on the observation
that the running sum value of a path p of length l at any index i can
be computed as
RSp[i]=bp[i]·(n−l)−l·(i−bp[i]). (2)
Here,
bp[i]=|{v∈Cp|r(v)≤i}| (3)
is the number of nodes on the path that have a rank less than or
equal to i. In order to compute the most signiﬁcant paths p∈Pl
of length l where l ranges from 1 to a user-deﬁned upper bound
m, we will ﬁrst focus on the subset Pl(vk) of paths that end in a
certain node vk and have a ﬁxed length of l. Hereby, we will derive
a recurrence scheme that allows to solve the problem for all nodes
and the considered range of path lengths in an efﬁcient manner.
2.3 The dynamic programming algorithm
Observation 2 implies that the best score of any path p of length l
ending in vk can be computed as
M[l,k]= max
i=1,...,n
{M[l,k,i]·(n−l)−l·(i−M[l,k,i])},
where
M[l,k,i]= max
p∈Pl(vk)
bp[i]. (4)
In this section, we will derive the recurrence scheme for ﬁlling the
3D matrix M[l,k,i] of size m·|V|·n.I fM has been ﬁlled, we can
easily calculate the best running sum score for any length l and any
node vk and the corresponding paths can be determined by a simple
standard backtracking procedure. If no path of length l ending in
node vk exists, we set M[l,k,i]=−1 for all indices i=1,...,n.
Since the path of length 1 ending in a node vk consists only of the
node vk itself, the computation of the ﬁrst matrix layer M[1,k,i] is
straightforward:
M[1,k,i]=

1 : r(vk)≤i
0 : r(vk)>i
In the following, we derive the recurrence formula that allows for
computing all values M[l,∗,∗] of layer l from the values M[l−
1,∗,∗] of layer l−1. The idea behind the approach is similar to
the principle used in shortest/longest path calculations. In order to
compute the best path of length l leading to vk, we determine the
optimal paths of length l−1 ending in one of the predecessor nodes
vs∈N(vk) and add the path of length 1 consisting of the node vk:
M[l,k,i]=

maxvs∈N(vk)M[l−1,s,i]+1 : r(vk)≤i
maxvs∈N(vk)M[l−1,s,i]: r(vk)>i
(5)
The pseudocode for ﬁlling the layers 2–m is presented below:
for (l in 2..m)
for (i in 1..n)
for (k in 1..|V|)
if (N(vk)==∅|| q:=maxvs∈N(vk)M[l−1,s,i])==−1)
M[l,k,i]:=−1
else
if (r(vk)<=i)
M[l,k,i]:=q+1
else M[l,k,i]:=q
Here, the ﬁrst if-statement evaluates whether any path of length l
ends in vk. If this condition does not hold, M[l,k,i] is set to −1.
Otherwise, the value M[l,k,i] is calculated via the recurrence in
Equation (5). Since we had to avoid cycles, we added a further
condition which is not listed in the pseudocode described above: our
algorithm searches for the best path ending in one of the predecessor
nodes vs∈N(vk) that does not contain node vk.
The running time of the procedure is of order O(m·n·(|V|+|E|))
where |E| is the number of edges of the graph G. Since the number
n of genes in the list S is usually much larger than the number |V|
of nodes in G and since the maximal scores of the running sums
will only appear at list positions where a node of the graph occurs,
we can easily reduce the running time to O(m·|V|·(|V|+|E|)) by
iterating only over the sublist of indices in S that represent the nodes
V of G. The presented procedure requires O(m·n·|V|+|E|) storage.
If we are computing and storing the best paths for each node vk
and the different lengths l while ﬁlling the matrix, the backtracking
process is not required. Under these conditions, the layer M[l−
1,∗,∗] sufﬁces to calculate the next layer M[l,∗,∗] and, hence, only
storage for two layers is required for the dynamic programming
algorithm, in addition to the data structure for the calculated optimal
paths. Since we have to store m paths of length 1 to m for each node,
the data structure for the optimal paths requires O(m2·|V|) storage.
Without affecting the results of the computation, the order of the
nested for-statements in the procedure above can be changed such
that the outer for-loop iterates over the gene list S (i=1,...,n) and
the inner for-loops over the nodes vk and the length l. Hence, the
wholeprocedurecanbecarriedoutwithtwolayersofsizem·n.With
the same argument as above, we can reduce the storage requirement
of two layers to O(m·|V|) by considering only the sublist of S that
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consists of the nodes V. Hence, the whole procedure requires O(m2·
|V|+|E|) storage.
Ofcourse,itcannotbeguaranteedthatthebestpathswiththemost
signiﬁcant P-values are the ones we should be after. The FiDePa
algorithm can be adapted such that paths with lower signiﬁcance
values are computed at additional computational cost and storage.
In particular, we can modify the algorithm such that it allows
for computing a constant number of (sub)optimal paths for each
node and each length without changing time or space complexity.
However, our current implementation enables the user to identify a
large variety of signiﬁcant paths since we are searching for paths of
different lengths and since we are scanning all nodes in the graph
(signiﬁcant paths that end or start in one the nodes of the network).
For the running sum values, P-values can be easily computed as
described in (Keller et al., 2007). Because of the multiple testing
problem, the P-values of all nodes have to be adjusted. We applied
an adjustment based on controlling the false discovery rate (FDR;
Benjamini and Hochberg, 1995; Hochberg, 1988).
We implemented the FiDePa algorithm in C++.As input, FiDePa
gets a sorted list of genes and a BNDB (Kuentzer et al., 2007) mysql
databasecontainingallhumanregulatoryinteractionsextractedfrom
the KEGG andTRANSPATH database.The latter database provides
information on signaling molecules as well as metabolic enzymes
andthereactionstheyareinvolvedin,formingacomplexnetworkof
interconnected reaction chains and complex pathways.The pathway
information is extracted from the mysql database, the graph is built,
and the gene expression data are projected onto the nodes (genes)
of the graph. Since for some nodes, no expression values exist, our
algorithm does not consider the respective nodes. For each node
without the expression value, only the predecessors with expression
values are considered.
As output, the algorithm provides a set of statistically signiﬁcant
paths as a plain text ﬁle. In addition to this plain text ﬁle, we also
implemented a plug-in for the network visualizer BiNAto facilitate
the interpretation of the relevant paths.
2.4 Computation of the sorted gene list via z-scores
To compute the sorted list S, we used so-called standard scores
(z-scores) that allow for comparing observations from different
normal distributions. The z-score of a given value shows by how
many SDs this value is above or below the mean of a background
distribution. For each transcript t, we computed its mean value µt
and its SD σt based on 158 normal expression values. For a given
cancer proﬁle, we computed the z-score zt for transcript t with
expression value xt as follows:
zt =
xt−µt
σt
.
Hence, a z-score zt of 3 means that the expression value of the
transcript t of the considered cancer sample is 3 SDs above the
mean of the transcript in normal samples. Likewise, a z-score of −3
means that the expression value of t is 3 SDs below the mean of the
transcript in normal samples.
TogeneratethelistS foragivencancerproﬁle,theabsolutevalues
of the z-scores of all genes were sorted in decreasing order such that
the most deregulated genes occur on the top of the list.
Fig. 1. BiNA GUI for the visualization of the FiDePa results.
2.5 Visualization
If we are applying our novel algorithm, e.g. to a set of cancer
expression proﬁles that will be compared with expression proﬁles
from a control group, our algorithm computes and outputs the
signiﬁcant paths for each cancer proﬁle (tumor, patient) separately.
Afterwards the algorithm calculates the so-called consensus graph
as the union of all paths detected in at least one of the patients.
The plug-in for the network visualizer BiNA enables the user to
upload the paths of a single patient and to visualize these paths as a
highlightedsubgraphoftheconsensusgraph.Furthermore,theplug-
in also facilitates the comparison of deregulated processes between
two tumors (or groups of tumors) by allowing the user to load two
sets of deregulated paths.The paths will be mapped to the consensus
graph and highlighted in different colors. Here, edges are colored
according to the following scheme: edges that are signiﬁcant in both
proﬁlesaremarkedgreen,edgesthataresigniﬁcantintheﬁrstproﬁle
are marked blue and edges that are signiﬁcant in the second proﬁle
are marked red. Moreover, BiNAalso offers an overview of the edge
or reaction frequencies, i.e. the thickness of the edges indicates how
often certain reactions have been detected in the different cancer
proﬁles. The BiNA graphical user interface (GUI) for visualizing
FiDePa results is presented in Figure 1.
3 RESULTS
Wehaveappliedournoveldynamicprogrammingalgorithmtostudy
deregulated signaling cascades in glioma tumors. To this end, we
analyzed 100 glioma expression proﬁles of WHO grades III and IV
(Phillipsetal.,2006).Fortherespectivepatients,avarietyofclinical
and histological data including the WHO grade, microvascular
proliferation status, necrosis and survival times, are available. As
background distribution, we used 158 expression proﬁles (GDS596;
Su et al., 2004) of physiologically unaffected tissues. Control and
cancer expression proﬁles were downloaded from the GEO and
all proﬁles were quantile normalized (Bolstad et al., 2003). Then,
for each transcript, the mean value and the SD of the transcript
in the control proﬁles were computed. For all transcripts of each
cancer proﬁle, the z-scores (details to the computation of z-scores
can be found in Section 2.4) of the transcripts were calculated
2790[12:21 30/9/2009 Bioinformatics-btp510.tex] Page: 2791 2787–2794
A novel algorithm for detecting differentially regulated paths
Fig. 2. FiDePa workﬂow.
and corresponding genes were sorted with respect to the absolute
value of their z-scores in a decreasing order, resulting in one sorted
gene list for each cancer proﬁle. The input of the FiDePa algorithm
consisted of the sorted z-score lists and the union of the KEGG
and TRANSPATH networks that was imported from our BNDB
database (Kuentzer et al., 2007). For each cancer proﬁle, we carried
out the following computation steps: the z-scores of the genes
present in the network were assigned to the corresponding nodes,
the ranks of the nodes were calculated, the dynamic programming
algorithm was carried out and the resulting paths plus their P-values
were computed as described in Section 2.2. Hereby, the considered
path lengths ranged from 2 to 8 edges. Afterwards, the consensus
graphunifyingalldetectedpathswasconstructedandstored.Finally,
we analyzed the obtained results by carrying out comprehensive
statistical tests that will be described below. The workﬂow of the
whole analysis procedure is summarized in Figure 2.
3.1 Glioma paths
First, we studied the glioma consensus graph, consisting of the
union of edges that proved to be signiﬁcant in at least one of the
analyzed glioma expression proﬁles. The consensus graph consisted
of a total of 192 nodes and 549 edges. The genes that occurred most
frequently in the deregulated subnetworks are ATF4 (45), ELK1
(43), DDIT3 (39), MAP2K2 (38), MAPKAPK5 (37), ATF2 (36),
MOS (36), TP53 (36), JUN (34), MAP2K7 (34), CDC25B (32),
MAP2K3 (32), MAP3K10 (32), MYC (32), ELK4 (31), MAP2K1
(31) and MAPT (31). Here, the numbers in brackets denote the
number of cancer proﬁles where FiDePa detected paths, containing
therespectivegenes.Aliteratureinquiryrevealedthatallthesegenes
are closely connected to cancer development or progression, most of
themarealsodirectlyconnectedtoglioma.Asthegenelistindicates,
many of the above genes belong to the MAPK (mitogen-activated
protein kinase) signaling pathway or to the Apoptosis pathway. To
detect the signiﬁcantly enriched biochemical pathways, we used
the web-based tool GeneTrail (Backes et al., 2007). We carried
out an overrepresentation analysis, comparing the genes of the
consensus network to all human genes using GeneTrail’s standard
parameters.Ouranalysisrevealedatotalof26signiﬁcantlyenriched
KEGG pathways (Table 1). On top of the results list appeared
the ‘MAPK signaling pathway’, with an expected number of 18
genes and an observed number of 69 genes. The pathway with the
second best signiﬁcance value was the ‘Natural killer cell-mediated
cytotoxicity’, with an expected number of 9 genes and an observed
number of 34 genes, followed by the ‘Apoptosis’ with 25 observed
genes and 5 expected genes. The list, of course, entailed several
cancer pathways, including colorectal cancer, pancreatic cancer and
glioma.
To compare the results of our FiDePa algorithm with an
analysis, which does not consider the network topology, we
carried out a standard GSEA by using the GeneTrail web
server (Backes et al., 2007). The results of the computation for
KEGG and Transpath pathways, TRANSFAC transcription factors,
gene ontologies categories and others can be reviewed online
at http://genetrail.bioinf.uni-sb.de/paper/ﬁdepa/summaryPage.html.
The KEGG pathway analysis identiﬁed 16 enriched pathways,
including several pathways that were also identiﬁed by FiDePa,
e.g. the ‘Natural killer cell-mediated cytotoxicity’ or the ‘T-cell
receptor signaling pathway’. However, some clearly cancer-related
pathways including ‘Apoptosis’, ‘Glioma cancer’, ‘Pancreatic
cancer’, ‘MAPK signaling pathway’and others were only identiﬁed
by the FiDePa analysis, while they were missed using the standard
GSEA.
3.2 Clustering of signiﬁcant networks
To validate whether the detected paths can be exploited to
differentiate between histological or clinical states, we performed
a complete linkage hierarchical clustering. To this end, we encoded
the subnetworks of the consensus graph belonging to one cancer
proﬁle as binary vectors, where each vector component represents
one reaction. A vector entry of ‘1’ means that the respective
edge has been detected in at least one signiﬁcant path of the
respective tumor proﬁle. As a distance measure for the clustering,
we used the Manhattan distance between the binary vectors. In
a preprocessing step, we removed edges that occurred in <10%
of the patients, reducing the number of edges to 96. Likewise,
we excluded the patients for whom no clinical information was
available.WeconsideredtheWHOgradesIIIandIV,necrosisstatus,
microvascular proliferation and the survival rates of patients.
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Table 1. Signiﬁcant KEGG pathways on the consensus network
Pathway No. exp. No. obs. Sig.
genes genes value
MAPK signaling pathway 18 69 1.6−25
Natural killer cell-mediated cytotoxicity 9 34 1.39−11
Apoptosis 5 25 9.29−11
Epithelial cell sig. in Helicobacter
pylori infection
31 75 .01−10
Focal adhesion 9 26 2.52−06
Adherens junction 5 18 1.38−05
T-cell receptor signaling pathway 5 18 1.46−05
Chronic myeloid leukemia 4 16 1.65−05
Fc epsilon RI signaling pathway 4 16 1.85−05
Toll-like receptor signaling pathway 5 17 5.53−05
Colorectal cancer 2 10 9.40−05
Pancreatic cancer 4 14 0.0001
Cytokine–cytokine receptor interaction 14 30 0.0001
Adipocytokine signaling pathway 4 14 0.0001
mTOR signaling pathway 2 10 0.0002
GnRH signaling pathway 6 17 0.0003
B-cell receptor signaling pathway 4 11 0.0013
Insulin signaling pathway 9 20 0.0013
Cell cycle 5 13 0.0014
Glioma 4 11 0.003
Type II diabetes mellitus 3 9 0.0033
VEGF signaling pathway 5 12 0.0059
Type I diabetes mellitus 0 3 0.0059
Leukocyte transendothelial migration 5 11 0.0135
Axon guidance 8 15 0.0173
Maturity onset diabetes of the young 2 5 0.0386
Splitting the cluster dendrogram in two clusters, we found one
cluster containing nine WHO III and 12 WHO IV samples and
one cluster containing two WHO III and 24 WHO IV samples.
The P-value for this result, computed using Fisher’s exact test,
was 0.0056. Examining the proliferation of tumor cells, we
found one cluster containing seven samples without microvascular
proliferation and four samples with microvascular proliferation.
The second cluster contained four samples without microvascular
proliferation and 27 samples with microvascular proliferation. The
respective P-value was 0.0026. With respect to the necrosis of
tumor cells, we found one cluster containing nine samples not
showing necrosis and two samples with necrosis. The second
cluster contained six samples without necrosis and 25 samples with
necrosis.TherespectiveP-valuewas0.0004.Additionalinformation
on the paths differing between the long- and short-time survivors
and the grade III versus grade IV patients are provided in the
Supplementary Material.
3.3 Single patient analysis
To demonstrate the applicability of the FiDePa algorithm, we
compared two WHO grade III gliomas, both without microvascular
proliferation and necrosis. Both patients were of similar age with
39 and 35 years. However, the respective survival time were quite
different with 41 weeks and 477 weeks. The comparison of the
deregulated networks of both tumors revealed a very small overlap,
as shown in Figure 3.
Fig. 3. BiNA visualization of the two patients A (blue, survival time 477
weeks) and B (red, survival time 41 weeks). Edges on signiﬁcant paths in
both tumors are colored green. The network shows the relevant part of the
complete consensus network, whereas the non-relevant part of the consensus
network is presented by gray edges and nodes in the background.
4 DISCUSSION
In this work, we presented a dynamic programming algorithm that
aims at detecting the signiﬁcantly deregulated signaling cascades in
tumor cells. The FiDePa algorithm interprets expression differences
between tumor and normal tissue and relies on GSEA. Since FiDePa
enables the comparison of a single tumor expression proﬁle with the
control group, it provides information on regulatory features that
are speciﬁc for the corresponding tumor and that can contribute to a
personalized medicine by tailoring the tumor therapy to the speciﬁc
regulatory tumor features identiﬁed by FiDePa.
The application of FiDePa to a glioma dataset showed that the
algorithm is able to detect the relevant signaling cascades that are
known to be glioma and/or cancer related. The most signiﬁcant
pathway was the MAPK signaling cascade, followed by the Natural
killer cell-mediated cytotoxicity and theApoptosis. It is well known
that both pathways are deregulated in glioma: the MAPK signaling
cascade, e.g. is described to be deregulated in glioma in various
studies (Chattopadhyay et al., 2002; Cuevas et al., 2006; Kam
et al., 2007; Schlegel et al., 2000). An upregulation of the MAPK
signaling cascade in cultured glioma cells mediated by ﬁbroblast
growth factors indicated that MAPK pathway participates in the
FGF-dependent glioma development (Cuevas et al., 2006). As for
the MAPK signaling pathway, we were able to retrieve all other
signiﬁcant pathways in the glioma literature, providing evidence for
the effectiveness of the FiDePa algorithm. However, besides the
results coherent with the ﬁndings in the literature some additional
glioma-related pathways are cited in the literature. For example,
Phillips et al. (2006) suggest that Akt and Notch signaling are
hallmarksofapoorprognosisofgliomas,whilethesepathwayswere
not ostentatious in our work. This, however, might be explained
by the fact that our FiDePa analysis did not focus on prognosis,
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but on the comparison of glioma and normal tissue. In 2008, two
large-scale integrated studies on glioblastoma have been published
by McLendon et al. (2008) and Parsons et al. (2008). McLendon
and co-workers identiﬁed ERBB2, NF1 and TP53 as key players
in glioblastoma together with the RTK signaling, the p53 and
RB tumor suppressor pathways. In our expression pattern-based
study, we identiﬁed the TP53 component, while the other pathways
play a less important role. In contrast to our results, the MAPK
signaling cascade is non-signiﬁcant in the study of McLendon
et al., which is based on genetic alterations including validated
somatic nucleotide substitutions, homozygous deletions and focal
ampliﬁcations. Parson and co-workers identiﬁed the gene IDH1 as
CAN-gene (candidate cancer gene) by integrating of sequencing,
copynumberandexpressiondata.However,thisgenedoesnotshow
signiﬁcant deregulation in our data and thus is not included in our
consensus network. Other CAN genes identiﬁed by Parson et al.
were included in our network, e.g. TP53, RB1 or EGFR.
An unsupervised cluster analysis demonstrated that a clustering
based on the detected paths subdivides the tumors into groups that
correlate well with different clinical states. Moreover, we found
substantiallydifferentpathsfortwopatientswithstrikinglydifferent
survivaltimesbutwithtumorsofotherwisesimilarclinicalbehavior.
Our results conﬁrm that tumors of the same type can be rather
heterogeneous. As discussed above, the consensus network of all
patients contains most pathways that are known to be glioma or
cancer related. However, the consensus network of a single patient
is only a subnet of the complete consensus network revealing the
regulatory pathways (mechanisms) that are deregulated or most
signiﬁcantly modiﬁed in this tumor. Hence, the approach may detect
differences in the active oncogenic mechanisms that may help to
optimize the therapy for each patient individually.The vision behind
our project is to develop a visual analytics tool that supports doctors
in making therapeutical decisions. Such a tool should offer not only
functionality for analyzing and visualizing deregulated signaling
cascades,butalsoaccesstoadatabasestoringderegulatedconsensus
networks of patients together with their clinical data, especially the
therapeutic history.
In this work, the FiDePa algorithm has been applied for studying
regulatory networks, which play an essential role for cancer
development and progression. However, our algorithm can of
course be applied to arbitrary networks, including protein–protein
interaction networks. Here, an additional preprocessing step is
necessary for matching the proteins in the network to the genes
in the sorted list.
In the light of the ongoing discussion on the quality and
effectiveness of gene set analysis methods (Ackermann and
Strimmer, 2009; Holden et al., 2008; Lin et al., 2008), we would
like to underline that our dynamic programming approach can be
easily adapted to other gene set analysis method or gene scoring
approaches, e.g. Wilcoxon rank-sum test, median, mean, SAMGS
and some other approaches discussed in Ackermann and Strimmer
(2009). Actually, the dynamic programming algorithm can be
simpliﬁed for most of the other gene set analysis methods. However,
the direct P-value computation usually has to be replaced by more
laborious permutation tests.
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